Male climacteric syndrome: Late Onset Hypogonadism (LOH) in males / 대한내과학회지

Male climacteric syndrome is a clinical and biochemical syndrome characterized by the decline in serum concentration of biologically active forms of testosterone with aging in men which may result in detrimental effect on the quality of life(QOL) and adversely affect the function of multiple organ systems. Androgen replacement therapy may have favorable effect in QOL, body composition, cardiovascular disease, sexual dysfunction and osteoporosis. Controversy in defining the clinical syndrome and in long-term effect of androgen replacement therapy continues. An international consensus document was recently published and provides guidance on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in males. The diagnosis of LOH requires biochemical and clinical components. Any clinical intervention testosterone treatment should be judged on a balance of risk versus benefit. There have been potential concerns regarding the effects of testosterone on prostate disease and polycythemia. The available treatment methods have increased in recent years with the availability of a number of testosterone preparations which can reliably produce physiological serum concentrations. Periodic physician's evaluations is required to assess the clinical response and to avoid potential adverse events and must be tailored individually.

Genetic Association Research between Mutation in CYP1A2 Gene and Erxian Soup Response / 中国中医药信息杂志

Objective To investigate the genetic association between mutation in cytochrome P450 1A2 (CYP1A2) gene and Erxian suop response. Methods Forty-eight patients with male climacteric syndrome of both Yin and Yang deficiency received a treatment of erxian suop with three months. The severity of symptoms and responses to Erxian suop were quantizated by the method of Department of Psychology in Istanbul Bosphorus University and Clinical Research Guidance Principle on New Drug of Traditional Chinese Medicine published by China. A single nucleotide polymorphism (SNP) at position 2964 (G-A) of CYP1A2 gene were identified by polymerase chain reaction (PCR) in order to analyse the relationship between Erxian response and CYP1A2 single nucleotide polymorphism. Results Statistical analysis showed there was no significant difference among genetype and genetype distribution of CYP1A2 G2964A between the patients and control group. The genotype of the 16 patients among 32 effective patients was G/G (56.25%). The genotype of the 11 patients among 16 ineffective patients was G/A (68.75%). There was no significant difference in symptoms, physical sign between the two groups at the pre-treat and post-treat. Also the two groups had no significant difference among the score of major symptoms and hyposymptoms. Conclusion The patients with genotype of G/G have higher efficiency, while with genotype of G/A have lower efficiency among patients with CYP1A2 G2964A gene when treated with erxian soup.

Clinical Study on Treatment of Climacteric Syndrome With Yixinkangtai Capsules in Males / 中国药房

OBJECTIVE:To study the therapeutic efficacy of Yixinkangtai capsules(YXKT)on climacteric syndrome in males.METHODS:360cases of male climacteric syndrome randomly divided into2groups:trial group(220cases)was treated with YXKT for3wks and control group(140cases)received placebo.RESULTS:In the trial group,the rate of symptomatic improvement was74.3%.Before and after3-week treatment,blood testosterone levels were(131.51?19.12)mg/L and(253.78?21.45)mg/L;SOD levels were(1068?121.4)IU/(g?Hb)and(1178.1?132.6)IU/(g?Hb),MDA levels were(7.6?0.8)?mol/L and(5.8?0.6)?mol/L respectively,and depression score was improved as well.There were significant dif?ferences in all above-mentioned parameters between2groups.CONCLUSION:YXKT is effective and safe for treating cli?macteric syndrome in males.